Type B Aortic Dissections: Treating the Many to Benefit the Few?
Overview
Affiliations
Purpose: It is now more than a decade since aortic stent-grafts were introduced clinically to provide a less invasive and potentially less harmful therapeutic option to treat type B aortic dissections. However, recent publications on best medical treatment and quality of life in patients with chronic type B dissection support conservative treatment due to the low incidence of aneurysm formation, rupture, and disease-related complications. Against this backdrop, we analyzed our experiences and now discuss whether the availability of endografts allowed us to change indications toward a more aggressive endovascular approach to acute and non-complex type B dissections, seeking to determine which patients we should treat and which ones we should observe.
Methods: Between 1997 and 2008 in our institution in Heidelberg, we treated 172 patients with acute and chronic type B dissections, most (n = 118, 69%) conservatively. However, 54 patients (40 men; mean age 57 years, range 30-82) underwent endovascular repair; 43% (n = 23) were emergency cases. Patients were followed periodically with computed tomographic angiography.
Results: Correct stent-graft deployment was achieved in 50 (93%) patients; the left subclavian artery was intentionally covered in 30 (55%) cases. Two carotid-subclavian bypass grafts were performed at the time of the endovascular repair due to partial coverage of the left common carotid artery. The perioperative complication rate was 19% (n = 10), but there were no neurological sequelae. The 30-day mortality rate was 11% (n = 6). Over a mean 32.1+/-25 months, 4 other patients died (18.5% overall mortality rate); survival estimates by Kaplan-Meier analysis were 80.4% and 66.1% after 1 and 5 years, respectively. Complete false lumen thrombosis was observed in 32 (60%) and a persisting completely patent false lumen in 3. The aortic expansion rate was 31% (17/54) overall. No difference was found between acute and chronic dissections in terms of survival (p = 0.247).
Conclusion: Despite a minimally invasive approach, complication and mortality rates for endovascular therapy of type B aortic dissections are considerable. Endografting is limited to symptomatic patients and those with chronic large aneurysmal expansion. At this stage in stent-graft development, asymptomatic patients benefit more from conservative treatment.
Questions and Certainty in Diagnosis and Management of Acute Type B Aortic Dissection.
Lovato L, Cocozza M, Onori A, Fattori R Rev Cardiovasc Med. 2025; 26(2):26807.
PMID: 40026512 PMC: 11868877. DOI: 10.31083/RCM26807.
Early and Late Mortality Predictors in Patients with Acute Aortic Dissection Type B.
Lasica R, Perunicic J, Popovic D, Mrdovic I, Arena R, Radovanovic N Cardiol Res Pract. 2022; 2022:7869356.
PMID: 36471803 PMC: 9719417. DOI: 10.1155/2022/7869356.
Yuan X, Mitsis A, Ghonem M, Iakovakis I, Nienaber C J Vis Surg. 2018; 4:59.
PMID: 29682469 PMC: 5897677. DOI: 10.21037/jovs.2018.02.15.
Liu Z, Zhang Y, Liu C, Huang D, Zhang M, Ran F J Int Med Res. 2017; 45(5):1574-1584.
PMID: 28701057 PMC: 5718725. DOI: 10.1177/0300060517708893.
Moulakakis K, Mylonas S, Dalainas I, Kakisis J, Kotsis T, Liapis C Ann Cardiothorac Surg. 2014; 3(3):234-46.
PMID: 24967162 PMC: 4052408. DOI: 10.3978/j.issn.2225-319X.2014.05.08.